Exploring Three High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a decline of 4.1%, yet it has shown resilience with a 6.6% increase over the past year, and earnings are anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation despite short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	26.18%	37.61%	★★★★★★
Alkami Technology	20.45%	85.16%	★★★★★★
Travere Therapeutics	28.43%	65.01%	★★★★★★
AVITA Medical	27.78%	55.33%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	22.82%	58.64%	★★★★★★
Blueprint Medicines	22.49%	55.91%	★★★★★★
TKO Group Holdings	22.54%	25.17%	★★★★★★
Alvotech	31.17%	100.18%	★★★★★★
Lumentum Holdings	21.55%	119.67%	★★★★★★

Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Natera (NasdaqGS:NTRA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Natera, Inc. is a diagnostics company that provides molecular testing services globally, with a market capitalization of approximately $19.53 billion.

Operations: The company generates revenue primarily through the development and commercialization of molecular testing services, amounting to approximately $1.70 billion.

Natera, a player in the genetic testing and diagnostics sector, is navigating a path toward profitability with an expected annual profit growth of 54.11%, outpacing its industry's average. Despite current unprofitability, its strategic R&D investment, which aligns with its revenue growth at 13% annually, underscores a commitment to innovation in oncology and prenatal testing fields. Recent board expansions and clinical trials like HEROES indicate proactive governance and research depth. With a forecasted revenue upswing to $1.95 billion by year-end 2025 amidst robust earnings projections, Natera is positioning itself as a pivotal figure in biotech's evolution driven by precision medicine advancements.

• Dive into the specifics of Natera here with our thorough health report.

• Review our historical performance report to gain insights into Natera's's past performance.

Corning (NYSE:GLW)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Corning Incorporated operates in optical communications, display technologies, environmental technologies, specialty materials, and life sciences sectors both in the United States and internationally, with a market capitalization of approximately $38.89 billion.

Operations: Corning generates revenue across several segments, with Optical Communications and Display Technologies being the largest contributors at $4.66 billion and $3.87 billion, respectively. Specialty Materials also plays a significant role with $2.02 billion in revenue, while Environmental Technologies and Life Sciences contribute $1.67 billion and $979 million, respectively.

Corning, a key innovator in materials science, is rapidly advancing in high-tech sectors through strategic R&D and partnerships. With an annualized revenue growth of 9.5% and earnings growth at 39.6%, the company demonstrates robust financial health amidst challenging market conditions. Recent collaborations, like supplying wafers and polysilicon for U.S.-made solar modules, underscore its commitment to domestic manufacturing and sustainability. This initiative not only leverages Corning's material science expertise but also aligns with increasing demand for renewable energy solutions, potentially boosting future revenues while supporting the industry's shift towards more sustainable practices.

• Click to explore a detailed breakdown of our findings in Corning's health report.

• Assess Corning's past performance with our detailed historical performance reports.

Phreesia (NYSE:PHR)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare sector in the United States and Canada, with a market capitalization of $1.40 billion.

Operations: The company generates revenue primarily from its healthcare software segment, which accounted for $419.81 million. The platform is designed to streamline operations in the healthcare sector across the United States and Canada.

Phreesia, navigating the competitive landscape of healthcare technology, has demonstrated a notable turnaround in its financial health. With a substantial reduction in net loss from $136.89 million to $58.53 million year-over-year and an increase in annual revenue by 17.8% to $419.81 million, the company is on a path to profitability, expected within three years. This growth trajectory is supported by strategic initiatives like the recent shelf registration aimed at raising nearly $70 million, potentially fueling further innovations and market expansion. Despite current unprofitability, Phreesia's aggressive investment in R&D and market strategies positions it as an emerging contender with promising prospects for growth exceeding industry averages.

• Click here to discover the nuances of Phreesia with our detailed analytical health report.

• Gain insights into Phreesia's past trends and performance with our Past report.

Seize The Opportunity

• Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 240 more companies for you to explore.Click here to unveil our expertly curated list of 243 US High Growth Tech and AI Stocks.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com